The Hatch-Waxman Act: How Generics Enter the Market

Introduction

The Drug Price Competition and Patent Term Restoration Act of 1984, universally known as the Hatch-Waxman Act, is the legal architecture that governs how generic drugs enter the US market. For healthcare bankers, Hatch-Waxman matters because it determines the timing and mechanics of the branded-to-generic transition, which is the most significant value-destruction event in pharma.

Hatch-Waxman created the Abbreviated New Drug Application (ANDA), which allows generic manufacturers to gain FDA approval by demonstrating that their product is bioequivalent to an already-approved branded drug, without repeating the full clinical trial program. This dramatically reduces the cost and time for generic approval (typically $1-5 million and 2-3 years, compared to $500 million+ and 8-12 years for a new drug NDA).

Bioequivalence

The scientific standard for generic approval under Hatch-Waxman. A generic drug is bioequivalent to the reference listed drug (RLD) if it delivers the same active ingredient, at the same rate and extent of absorption, in the same dosage form. The ANDA applicant must conduct bioequivalence studies (typically in 24-36 healthy volunteers) showing that the generic product's pharmacokinetic profile falls within 80-125% of the branded product's. This bioequivalence standard allows generics to rely on the branded company's clinical safety and efficacy data, avoiding the need for independent clinical trials.

The FDA maintains the Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the "Orange Book," which lists all approved drugs and the patents associated with them. When a generic company files an ANDA, it must certify one of four positions regarding each listed patent:

Paragraph IV certifications are the mechanism by which generics challenge branded patents before they expire, and they trigger the litigation process that determines entry timing.

The first generic company to file a substantially complete ANDA with a Paragraph IV certification receives 180 days of exclusive generic marketing. During this period, no other generic can be approved for the same drug, giving the first-to-file generic a temporary monopoly in the generic market.

This 180-day exclusivity period creates a powerful economic incentive. During the exclusivity period, the first generic typically prices at 15-20% below the branded price (compared to 80-90% below once multiple generics enter). A first-to-file generic for a $5 billion branded drug might generate $500 million-$1 billion in revenue during its 180-day exclusivity window.

Hatch-Waxman mechanics directly affect healthcare banking in several ways:

Patent cliff timing. The interplay between Paragraph IV challenges, 30-month stays, and litigation outcomes determines when generic entry actually occurs, which is often different from the headline patent expiration date. Healthcare bankers modeling LOE scenarios must assess the likelihood and timing of Paragraph IV challenges.

[Generic pharma valuation](/guides/healthcare-investment-banking/generic-pharma-business-model). The ANDA pipeline (number of pending ANDAs, first-to-file positions, and expected launch timelines) is the primary revenue driver for generic pharma companies. First-to-file positions are particularly valuable and are explicitly evaluated in generic pharma M&A.

The next article covers the drug supply chain and pricing mechanics that determine how drugs flow from manufacturer to patient and how revenue is captured at each step.